Identification and validation of tumor-associated macrophage-specific cGAS-STING axis-associated signature in melanoma progression: insights from multi-omics and in vitro validation

The cGAS-STING pathway serves as a critical innate immune sensor, yet its role in orchestrating the tumor microenvironment (TME) in melanoma (SKCM) remains controversial. Tumor-associated macrophages (TAMs) are abundant in SKCM and are key drivers of immunosuppression. However, the interplay between cGAS-STING activation in the TME and TAM polarization has not been systematically mapped. We utilized public multi-center bulk profiles of SKCM patients for identification of cGAS-STING and TAM (CT)-associated hub gene signature and overall survival (OS) stratification model for SKCM patients via various bioinformatic approaches, such as Limma, WGCNA, cox regression and integrated machine learning. Next, we also identified molecular and immune heterogeneity between CT-associated risk groups. In addition, molecular and immune patterns of CT-associated hub gene signature in TAM were assessed in SKCM patient single-cell level via various cutting-edge single-cell analytical frameworks at spatial and temporal manners. Drug sensitivity and deep learning-based drug screening were performed to identify potential drug repurposing approaches based on GDSC database and natural therapeutic candidates based on the ingredient of (FuFang KuShen, FFKS) targeting CT-associated hub gene for SKCM patients. Finally, in vitro assays validated the major findings of our study. We identified a CT-associated gene signature that effectively stratified SKCM patients into distinct risk groups with divergent immune landscapes, and nominated IL6, CXCL10 and ICAM1 as CT-associated and TAM-specific hub genes in SKCM progression. Furthermore, Tivantinib, NSC48300, Saracatinib can be considered as reproposing approaches targeting CT-associated hub gene in the treatment of SKCM. Novelty, Ingredient in FFKS (Matrine) can be considered as potential natural compound in the treatment of SKCM. Our study decodes the CT-associated molecular patterns in SKCM, highlighting TAM-specific hub genes as key mediators of tumor progression and offering a promising therapeutic avenue for precision oncology.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-19
DOI
https://doi.org/10.1007/s12672-026-06303-3
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identification and validation of tumor-associated macrophage-specific cGAS-STING axis-associated signature in melanoma progression: insights from multi-omics and in vitro validation

Peng Wang, Fen Shi, Yanxia Zhang, Guiying Feng et al.
Discover Oncology
Immune cells in cancer
article

Identification and validation of tumor-associated macrophage-specific cGAS-STING axis-associated signature in melanoma progression: insights from multi-omics and in vitro validation

Peng Wang, Fen Shi, Yanxia Zhang, Guiying Feng, Junyan Xu, Jing Wang, Qiyang Shou
article en

Abstract

The cGAS-STING pathway serves as a critical innate immune sensor, yet its role in orchestrating the tumor microenvironment (TME) in melanoma (SKCM) remains controversial. Tumor-associated macrophages (TAMs) are abundant in SKCM and are key drivers of immunosuppression. However, the interplay between cGAS-STING activation in the TME and TAM polarization has not been systematically mapped. We utilized public multi-center bulk profiles of SKCM patients for identification of cGAS-STING and TAM (CT)-associated hub gene signature and overall survival (OS) stratification model for SKCM patients via various bioinformatic approaches, such as Limma, WGCNA, cox regression and integrated machine learning. Next, we also identified molecular and immune heterogeneity between CT-associated risk groups. In addition, molecular and immune patterns of CT-associated hub gene signature in TAM were assessed in SKCM patient single-cell level via various cutting-edge single-cell analytical frameworks at spatial and temporal manners. Drug sensitivity and deep learning-based drug screening were performed to identify potential drug repurposing approaches based on GDSC database and natural therapeutic candidates based on the ingredient of (FuFang KuShen, FFKS) targeting CT-associated hub gene for SKCM patients. Finally, in vitro assays validated the major findings of our study. We identified a CT-associated gene signature that effectively stratified SKCM patients into distinct risk groups with divergent immune landscapes, and nominated IL6, CXCL10 and ICAM1 as CT-associated and TAM-specific hub genes in SKCM progression. Furthermore, Tivantinib, NSC48300, Saracatinib can be considered as reproposing approaches targeting CT-associated hub gene in the treatment of SKCM. Novelty, Ingredient in FFKS (Matrine) can be considered as potential natural compound in the treatment of SKCM. Our study decodes the CT-associated molecular patterns in SKCM, highlighting TAM-specific hub genes as key mediators of tumor progression and offering a promising therapeutic avenue for precision oncology.

Discover Oncology
Zhejiang Chinese Medical University (CN), Jinhua Academy of Agricultural Sciences (CN), Jinhua Central Hospital (CN)
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon